吴朝花,姜丰,苏菊,周雪,沈祥春,陶玲
WU Chaohua,JIANG Feng,SU Ju,ZHOU Xue,SHEN Xiangchun,TAO Ling

• 1:贵州医科大学中药药剂学教研室
• 2:贵州省高等学校天然药物药理与成药性评价特色重点实验室

摘要(Abstract)：

目的:考察改善氧化苦参碱(OMT)聚乳酸聚乙醇酸(PLGA)微球(MS)24 h累积释放百分率的制备工艺。方法:采用乳化溶剂挥发法(W/O/W)制备MS,保证载药量变化不大的情况下,以24 h累积释放百分率为指标考察聚乙烯酸(PVA)浓度、吐温浓度、搅拌速度、Na Cl浓度、PLGA浓度、外水相体积对MS体外释放的影响。结果:最优处方为PVA浓度为1%,Na Cl浓度为2%,PLGA浓度为125 g/L,外水相体积为100 m L,OMTMS载药量和包封率分别为28.95%、93.27%,24 h累积释放百分率为8.11%。结论:在该条件下制备OMT-MS24 h突释率得到改善。
Objective: To explore preparation technics for improvement of 24 h cumulative release percentage of oxymatrine( OMT) poly( 1actic acid-co-glycolie acid)( PLGA) microspheres( MS).Methods: By the Emulsified solvent evaporation( W/O/W),the effects of the concentration of PVA,Tween,Na Cl,PLGA and the stirring speed,external water phase volume on cumulative release percentage of OMT MS were investigated in the case of small changes in drug loading. Results: The optimal prescription: the concentrations of PVA,Na Cl,and PLGA were 1 %,2 %; and 125 g/L respectively; the volume of external water was 100 m L; the drug-loading rate and encapsulation efficiency of OMT-MS were 28. 95% and 93. 27% respectively,and the 24 h cumulative release percentage was8. 11%. Conclusion: The 24 h cumulative release percentage of microspheres could be improved when OMT-MS prepared under the mentioned condition.

关键词(KeyWords)： 氧化苦参碱;聚乙烯酸;聚乳酸-羟基乙酸共聚物;微球;24 h释放百分率;体外释放
oxymatrine;polyvinyle acid;polylactic acid-glycolic acid copolymer;microspheres;24 h cumulative release percentage;release in vitro

Abstract:

Keywords:

基金项目(Foundation): 贵州省科学技术基金[黔科合J字(2013)2039];; 贵州省科技厅社发公关项目[黔科合SY字(2015)3032];; 贵州省高层次创新型人才[黔科合人才(2015)4029号];; 贵州省高等学校科技创新团队[黔教合人才团队(2014)31号];; 贵州省科技创新团队[黔科合人才团队(2015)4025号]

作者(Author): 吴朝花,姜丰,苏菊,周雪,沈祥春,陶玲
WU Chaohua,JIANG Feng,SU Ju,ZHOU Xue,SHEN Xiangchun,TAO Ling

DOI: 10.19367/j.cnki.1000-2707.2017.06.011

参考文献(References)：

• [1]石磊,史丽娟.中药单体-氧化苦参碱药理作用研究新进展[J].山西医药杂志,20 15(2):123-126.
• [2]包玉羡.氧化苦参碱的药理作用与临床应用[J].世界最新医学信息文摘,2014(6):96-97.
• [3]赵先英,高继宁,粟永萍,等.乳酸-羟基乙酸共聚物多肽蛋白类药物微球控释系统的突释与控制[J].中国组织工程研究与临床康复,2011(38):7177-7180.
• [4]王恺源,高永良.影响PLGA微球突释的因素以及控制技术[J].中国新药杂志,2011(6):557-562.
• [5]冯晓健,吕秀玲,李学刚.改良复乳法(W/O/W)制备聚乳酸载药微球[J].河北理工大学学报,2010(2):91-93.
• [6]罗斌华,丁洁琼,阎志飞,等.阿霉素-PLGA微球体外释药特性的研究[J].解放军药学学报,2013(4):340-342.
• [7]缪阳,沈祥春,肖潮达,等.氧化苦参碱缓释微球的制备及体外释药性能的研究[J].中药材,2012(10):1675-1679.
• [8]Mao SR,Xu J,Cai CF,et al.Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres[J].International Journal of Pharmaceutics,2007(334):137-148.
• [9]Han YD,Tian HY,He P,et al.Insulin nanoparticle preparation and encapsulation into poly(lactic-co-glycolic acid)microspheres by using an anhydrous system[J].International Journal of Pharmaceutics,2009(378):159-166.
• [10]赵希青,孙晓雷,肖若蕾.PLGA微球的影响因素及控制技术[J].湖北科技学院学报,2015(29):451-453.
• [11]Xuan J,Lin Y,Huang J,et a1.Exenatide-loaded PLGA mi-crospheres with improved glycemic control:In vitro bioactivi-ty and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats[J].Peptides,2013(46):172.
• [12]齐献利.伊立替康微球突释效应的影响因素及控制方法[D].石家庄:河北科技大学,2015.
• [13]叶美娣,郑彩虹.乳酸-羟基乙酸共聚物(PLGA)微球控释系统的突释[J].中国现代应用药学杂志,2005(5):371-374.
• [14]Diab R,Brillauh J,Bardy A,et a1.Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer:efficiency for ex vivo alveolar mac-rophage targeting[J].Int J Pharm,2012(1-2):833.

文章评论(Comment)：